Holen Sie sich die Stockscreener-App
33.32
8.60%
2.64
Handel nachbörslich:
34.98
1.66
+4.98%
Schlusskurs vom Vortag:
$30.68
Offen:
$31.92
24-Stunden-Volumen:
1.11M
Relative Volume:
1.13
Marktkapitalisierung:
$3.15B
Einnahmen:
$4.72M
Nettoeinkommen (Verlust:
$-277.91M
KGV:
-8.933
EPS:
-3.73
Netto-Cashflow:
$-203.56M
1W Leistung:
-0.98%
1M Leistung:
+14.46%
6M Leistung:
-43.31%
1J Leistung:
-30.58%
1-Tages-Spanne:
$31.24
$33.58
1-Wochen-Bereich:
$30.35
$34.34
52-Wochen-Spanne:
$24.10
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Firmenname
Crinetics Pharmaceuticals Inc
Sektor
Branche
Telefon
858-450-6464
Adresse
6055 LUSK BLVD., SAN DIEGO, CA
Vergleichen Sie CRNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
33.32 | 3.15B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-25 | Eingeleitet | Stifel | Buy |
| 2025-02-11 | Eingeleitet | TD Cowen | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-01-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-01-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-12-21 | Eingeleitet | Jefferies | Hold |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-31 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-24 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-23 | Eingeleitet | ROTH Capital | Buy |
| 2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-08-13 | Eingeleitet | JP Morgan | Neutral |
| 2018-08-13 | Eingeleitet | Leerink Partners | Outperform |
| 2018-08-13 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2025 Earnings Call Transcript - Insider Monkey
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates - MSN
Crinetics Pharma’s Earnings Call: Positive Outlook Amid Challenges - TipRanks
Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and ... - Yahoo Finance
Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and Pivotal Launches on the Horizon - GuruFocus
Is Crinetics Pharmaceuticals, Inc. (CRNX) The Best Stock That Will Bounce Back? - Insider Monkey
Earnings call transcript: Crinetics Pharma stock rises after Q1 2025 results - Investing.com
Decoding Crinetics Pharmaceuticals Inc (CRNX): A Strategic SWOT Insight - GuruFocus
Crinetics (CRNX) Exceeds Revenue Expectations, Advances Key Projects | CRNX Stock News - GuruFocus
Crinetics Pharmaceuticals Q1 2025 Earnings: Revenue Surpasses Estimates at $0.4M, EPS Misses at -$1.04 - GuruFocus
Crinetics Pharmaceuticals Reports Progress on Paltusotine NDA and Atumelnant Phase 3 Study Amid Strong Financial Position - Nasdaq
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
11 Stocks That Will Bounce Back According to Analysts - Insider Monkey
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
What To Expect From Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings - GuruFocus
Closing Figures: Crinetics Pharmaceuticals Inc (CRNX)’s Negative Finish at 30.52, Down -9.30 - DWinneX
August 15th Options Now Available For Crinetics Pharmaceuticals (CRNX) - Nasdaq
Crinetics Pharmaceuticals (CRNX) Expected to Announce Earnings on Thursday - Defense World
How To Trade (CRNX) - news.stocktradersdaily.com
Crinetics Pharmaceuticals Inc (CRNX) stock on the rise: An overview - uspostnews.com
Top investors say Crinetics Pharmaceuticals Inc (CRNX) ticks everything they need - Sete News
Recent Insider Activity Suggests Potential Gains for Crinetics Pharmaceuticals Inc (CRNX) - knoxdaily.com
LPL Financial LLC Acquires 1,162 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Market Watch Highlights: Crinetics Pharmaceuticals Inc (CRNX) Ends on an Upturn Note at 33.39 - DWinneX
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock Holdings Boosted by Envestnet Asset Management Inc. - Defense World
Are Crinetics Pharmaceuticals Inc (CRNX) shares a good deal now? - uspostnews.com
CRNX stock touches 52-week low at $35.47 amid market shifts - MSN
Crinetics Pharmaceuticals patents new SSTR3 agonists - BioWorld MedTech
Wells Fargo & Company MN Increases Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Invesco Ltd. Acquires 42,954 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Russell Investments Group Ltd. Sells 43,501 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Affinity Asset Advisors LLC - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Unloaded Rep. Josh Gottheimer - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Alliancebernstein L.P. - Defense World
JPMorgan Chase & Co. Has $13.78 Million Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 | CRNX Stock News - GuruFocus
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 - The Manila Times
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants - GuruFocus
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Acromegaly Pipeline 2025: Detailed Clinical Trials - openPR.com
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Stock Surge: Crinetics Pharmaceuticals Inc (CRNX) Closes at 26.89, Marking a -6.86 Increase/Decrease - DWinneX
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Sei Investments Co. - Defense World
Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA - Seeking Alpha
CRNX stock touches 52-week low at $31.81 amid market challenges - Investing.com
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation Of Marketing Authorization Application (MAA) And Orphan Drug Designation (ODD) For Paltusotine In Acromegaly - MarketScreener
Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug - Marketscreener.com
Breakthrough: First Oral Acromegaly Drug Hits Major EU Milestone with Dual Regulatory Wins - Stock Titan
Finanzdaten der Crinetics Pharmaceuticals Inc-Aktie (CRNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):